NEW YORK (GenomeWeb News) — Applied Biosystems and Agilent have settled their patent suit concerning real-time thermal cycler IP and have forged a licensing arrangement, ABI said yesterday.
Under the agreement, Agilent will license “certain Applera technology” relating to Agilent’s real-time thermal cycler instruments for research use, but not in vitro diagnostics. Agilent will also license Applera technology relating to Agilent’s PCR and real-time enzymes and kits.
The settlement lifts injunctions in Germany and the Netherlands and pending cases in the US and France, and the settlement and agreement “fully resolve all pending disputes” between the companies.
The suit began in May 2007 when ABI parent Applera sued Stratagene, now part of Agilent, for alleging that Stratagene's Mx3000P, Mx3005P, Mx4000P, and "certain related reagents" infringe ABI’s EU patent No. 0 872 562 B1.
Stratagene at the time claimed that ABI’s claims were “without merit” and said it intended to “vigorously defend these actions.”
ABI today said that these agreements fully resolve all pending disputes between Applera and Stratagene.